IM Cannabis Corp.IMCC
Price (close)
$3.18
Market cap
—
P/E
—
Revenue (FY)
$54.7M
Net income
-$11.3M
Dividend yield
—
1-year total return
-94.0%
Net margin
-20.7%
Revenue growth
1.3%
Debt / equity
—
What IM Cannabis Corp. does.
and sale of medical cannabis products to medical patients in Israel and Germany. Following the regulatory reforms affecting cannabis access
in Germany on April 1, 2024, the cannabis market has experienced growth, especially within the medical sector, as access for new patients
has become easier. Since such time, we have shifted our focus and resources to concentrate on the burgeoning cannabis market in Germany.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.9M | $34.1M | $54.3M | $48.8M | $54.0M | $54.7M |
| Net income | -$28.7M | -$17.8M | -$188.9M | -$9.5M | -$10.6M | -$11.3M |
| Free cash flow | -$10.5M | -$39.0M | -$14.2M | -$8.7M | -$1.2M | $4.7M |
More on IMCC.
- IM Cannabis Corp. summary
- IM Cannabis Corp. financial statements
- IM Cannabis Corp. key metrics
- IM Cannabis Corp. health scores and style box
- IM Cannabis Corp. earnings
- IM Cannabis Corp. dividends
- IM Cannabis Corp. valuation
- IM Cannabis Corp. ownership and insiders
- IM Cannabis Corp. peers
Figures from IM Cannabis Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.